“First-Line Ipilimumab With Nivolumab Versus Immune Checkpoint Inhibitors With Tyrosine Kinase Inhibitors in Patients With Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma”. Journal of Kidney Cancer 12, no. 2 (April 25, 2025): 27–36. Accessed June 8, 2026. https://mail.jkcvhl.com/index.php/jkcvhl/article/view/387.